跳至主要内容
临床试验/CTRI/2021/04/033202
CTRI/2021/04/033202已完成不适用

Evaluation of skin safety of 3 test products for Primary Skin Irritation Using Skin Irritation Test (Patch Test in Humans). IS 4011:2018 Guidelines.

Lupin Ltd1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2021年3月5日最近更新:

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
60
试验地点
1
主要终点
Evaluation of cutaneous tolerance by dermatological scoring of skin reactions using Draize scale.

研究概览

简要总结

The test products,

- AB NEXT Gel - B No.:AB20003

-  Epiduo Gel - B No.: GU26

-  Deriva BPO Gel - B No.: 10200454

were dermatologically tested and found to be “Non-Irritant†based on IS 4011:2018Methods of Test for safety evaluation of cosmetics - Third Revision.

Basedon a* values,

Erythemadeveloped due to AB NEXT Gel was significantly lower as compared to erythema developeddue to Epiduo Gel and Deriva BPO Gel.

研究设计

研究类型
Interventional
分配方式
Not Applicable
盲法
Participant and Investigator Blinded

入排标准

年龄范围
18.00 Year(s) 至 60.00 Year(s)(—)
性别
All

入选标准

  • Fitzpatrick skin type III to IV.
  • Having apparently healthy skin on test area.
  • Willingness to avoid intense UV exposure on test site (sun or artificial UV), during the course of the study.

排除标准

  • Pregnancy (by history) and lactating women.
  • Scars, excessive terminal hair or tattoo on the studied area.
  • Hypersensitivity, allergy antecedent (to any cosmetic product, raw material, hair dye).

结局指标

主要结局

Evaluation of cutaneous tolerance by dermatological scoring of skin reactions using Draize scale.

时间窗: 48 hours

Evaluation of erythema using spectrophotometer (a value)

时间窗: 48 hours

次要结局

未报告次要终点

研究者

发起方
Lupin Ltd
申办方类型
Pharmaceutical industry-Global

研究点 (1)

Loading locations...

相似试验